- Home
- / Webinars & Videos
- / WEBINAR: Recent Advancements in Neurodegenerative Biomarkers
WEBINAR: Recent Advancements in Neurodegenerative Biomarkers
Posted on
Recent Advancements in Neurodegenerative Biomarkers: Progress Towards a Diagnostic Blood Test for Alzheimer’s Disease
With much enthusiasm following the research coming out of AD/PD™2021, we were pleased to bring together leading industry experts to discuss neurological advancements related to the ultra-sensitive quantification of pTau181, pTau217, pTau231, and other neurological biomarkers. This panel discussion and live Q and A covered the latest developments and opportunities to impact AD clinical trials and diagnostics.
The discussion was led by Quanterix Chairman, Chief Executive Officer, and President, Kevin Hrusovsky and featured Charlotte Teunissen, Ph.D., UMC Amsterdam, and Henrik Zetterberg, Ph.D., University of Gothenberg.
Share This Post
Related Posts
Akoya Biosciences Operations and Manufacturing Center of Excellence
Virtual Simoa® Success Seminar: North America 2024
On-Demand Recording Thanks for your interest in our Virtual Simoa® Success Seminar: North America 2024. Watch the replay of an exclusive virtual seminar featuring insightful presentations from Quanterix experts and Simoa®…
CTAD 2024 Quanterix Fireside Chat with Henrik Zetterburg: Advances in Blood-Based Biomarkers for Alzheimer’s Disease
The Clinical Trials on Alzheimer’s Disease (CTAD) conference brought together the world’s leading Alzheimer’s Disease (AD) researchers, with a major focus on the latest breakthroughs in blood-based biomarkers. These innovations…
Akoya: A Look Ahead on the Evolution of Spatial Biology (Peter Miller, PhD | Akoya Biosciences)
Quantitative Multiplex Assays for Pan-Cancer Immuno-Oncology Studies (Kathleen Pfaff, PhD | Dana-Farber Cancer Institute)
Correlation of Multiplex Immunofluorescence with RNA Sequencing (Zhongmin Xiang, PhD| BostonGene)
Unveiling the TME in Pancreatic Cancer: Unlocking the Potential of High-Resolution, Spatially Resolved Tissue Analysis (Andressa Dias Costa, MD | Dana-Farber Cancer Institute)